Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

Table 1 miRNAs: functions and targets in ovarian cancer

microRNAs	Function	Targets	Reference
miR-200 family	Tumor suppressor	ZEB1,ZEB2,β tubulin III	[31, 42, 45, 47, 48, 51–59, 111, 112]
	(Loss of EMT)
Let-7 family	Tumor suppressor	KRAS,HRAS,C-MYC,HMGA-2,CyclinA,D1,D2,D3,CDC25,CDK6	[47, 68–81, 110, 113, 116, 117]
	(Chemosensitization)
miR-34a/b/c	Tumor suppressor	c-myc,CDK6,Notch-1,MET,E2f3,Bcl2,cyclinD1	[82, 119]
	(Reduced invasion/migration/proliferation)
miR-100	Tumor suppressor	mTOR, PLK-1	[83–85]
	(Increased sensitivity to rapamycin analogs)
miR-31	Tumor suppressor	E2F2, STK40	[86]
	(Increased apoptosis)
miR-214/199a*	Oncogenic	PTEN	[51, 87–91, 93, 112]
	(Chemoresistance)
miR-376c	Oncogenic	ALK7	[21, 98]
	(Chemoresistance)
miR-93	Oncogenic	PTEN	[100–102]
	(Chemoresistance)
miR-21	Oncogenic	PTEN	[47, 51, 104–107, 112]
	(Chemoresistance)

miRNAs in ovarian carcinoma can either be oncogenic or tumor suppressor. Tumor suppressor miRNAs suppress oncogenes resulting in either loss of EMT (Epithelial Mesenchymal Transition), chemosensitization or tumor suppression. Whereas, oncogenic miRNAs target tumor suppressor genes leading to chemo resistance and reduced survival.